GMAB acquires MRUS for $97.00/sh cash—a 41% premium to Friday’s closing price: https://ir.genmab.com/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and The nominal deal value is $8.0B.